Gujarat Themis Biosyn (GUJTHEM) Share Price Falls 5.07% Today
- September 9, 2026
- Posted by: Harsh Piplani
- Category: News
Gujarat Themis Biosyn Share Price fell to Rs 430.15 today, down 5.07% or Rs 22.95 from the previous close of Rs 453.10. The company’s market capitalisation stood at Rs 5,897.17 crore. The Mid Cap pharmaceutical stock opened at Rs 463.00, touched a day high of Rs 463.00 and slipped to a day low of Rs 427.55, placing the counter in focus during the session.
The supplied data confirms a sharp single-day decline, but it does not establish any company-specific trigger. That is an important distinction. The current discussion is driven by verified market data such as price action, valuation and sector comparison, not by a disclosed catalyst in the dataset.
For investors tracking Gujarat Themis Biosyn Share Price today, the immediate picture is clear: the stock saw notable intraday weakness, turnover came in at Rs 1.57 crore, valuation remains elevated versus industry benchmarks, and profitability ratios still look stronger than broader sector medians. The practical question after such a move is whether the market continues to support premium multiples after this pullback.
Gujarat Themis Biosyn (GUJTHEM) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 430.15 |
| Previous Close | Rs 453.1 |
| Today's Move | -Rs 22.95 (-5.07%) |
| Open | Rs 463 |
| High | Rs 463 |
| Low | Rs 427.55 |
| Turnover | Rs 1.57 crore |
| Market Capitalisation | Rs 5,897.17 crore |
| Market Cap Category | Mid Cap |
The intraday structure was weak. The stock opened at Rs 463.00, which also remained the session high, and then moved down to Rs 427.55 before trading at Rs 430.15 at the time of the update. When the opening price also marks the day’s high, it generally indicates that sellers had control after the first print and the stock did not reclaim early levels during the session.
The decline of 5.07% is large enough to attract attention on its own, especially in a Mid Cap name. Turnover of Rs 1.57 crore indicates that the price move came with active trading rather than a static quote. Even so, the dataset does not explain the reason for the move, so any analysis must stay anchored to what is confirmed: the stock fell, the range was wide, and the closing trade at the update remained much closer to the day’s low than the high.
From a monitoring perspective, this leaves investors watching whether the stock stabilises around current levels or whether the pressure extends further. Without a stated trigger, market participants are more likely to judge the move through valuation, technical positioning and comparison with industry peers.
Gujarat Themis Biosyn (GUJTHEM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 5,897.17 crore |
| P/E Ratio | 121.12x |
| P/B Ratio | 5.62x |
| ROE | 21.69% |
| ROCE | 27.48% |
| EPS | Rs 3.74 |
| Book Value Per Share | Rs 80.59 |
| Dividend Yield | 0.15% |
The fundamental picture is not one-dimensional. Gujarat Themis Biosyn has a market cap of Rs 5,897.17 crore, a P/E ratio of 121.12 and a P/B ratio of 5.62. Those valuation numbers are high in absolute terms. At the same time, profitability metrics are firm, with ROE at 21.69% and ROCE at 27.48%.
EPS stands at Rs 3.74, while book value per share is Rs 80.59. The dividend yield is 0.15%, which points to a modest payout relative to the prevailing market price. Put together, these numbers show a company where the market is assigning a premium multiple to earnings and net worth, while also rewarding relatively strong return ratios.
That is why today’s decline does not automatically signal weak fundamentals from the supplied dataset. Instead, it sharpens the debate around valuation support. When a stock trades at a rich multiple, even a single day of price weakness can lead investors to reassess how much optimism is already built into the quote.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 121.12x |
| Benchmark Median P/E | 32.19x |
| Benchmark Average P/E | 49.13x |
| Benchmark P/E Range | 3.39x to 668.68x |
| Company P/B Ratio | 5.62x |
| Benchmark Median P/B | 3.05x |
| Benchmark Average P/B | 4.44x |
| Company ROE | 21.69% |
| Benchmark Median ROE | 11.82% |
| Benchmark Average ROE | 11.12% |
| Company ROCE | 27.48% |
| Benchmark Median ROCE | 13.71% |
| Benchmark Average ROCE | 13.62% |
| Company Market Capitalisation | Rs 5,897.17 crore |
| Benchmark Median Market Cap | Rs 715.6 crore |
| Benchmark Average Market Cap | Rs 14,150.82 crore |
Gujarat Themis Biosyn operates in Healthcare under Pharmaceuticals & Drugs, and the benchmark set covers 201 companies from the same industry. Within that universe, its P/E of 121.12 sits well above the median of 32.19 and the average of 49.13. Its P/B of 5.62 is also above the median of 3.05 and the average of 4.44.
Profitability is where the comparison turns more favourable. ROE of 21.69% is ahead of the industry median of 11.82% and average of 11.12%. ROCE of 27.48% is similarly above the median of 13.71% and average of 13.62%. So the stock does not screen as expensive without support from return ratios; rather, it screens as premium-valued alongside stronger-than-average profitability.
On size, the company’s market capitalisation is above the industry median of Rs 715.60 crore but below the average of Rs 14,150.82 crore. That places it in the middle of a very broad listed pharma landscape: larger than many smaller companies in the set, yet much smaller than the biggest established sector names.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,55,825.66 | 37.31 | 5.22 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,47,018.51 | 86.86 | 14.38 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,86,874.73 | 86.55 | 21.03 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,15,211.69 | 25.42 | 4.25 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,12,773 | 33.17 | 3.18 | 11.83 | 16 |
The peer set underlines why the valuation conversation matters. Gujarat Themis Biosyn trades at a P/E of 121.12, above Sun Pharma at 37.31, Divi’s Laboratories at 86.86, Torrent Pharmaceuticals at 86.55, Zydus Lifesciences at 25.42 and Cipla at 33.17. That makes its earnings multiple richer than every peer listed in this comparison.
On P/B, the company’s 5.62 is close to Sun Pharma’s 5.22, above Zydus Lifesciences at 4.25 and Cipla at 3.18, but below Divi’s Laboratories at 14.38 and Torrent Pharmaceuticals at 21.03. Profitability remains a relative strength: ROE of 21.69% is above Sun Pharma, Divi’s, Zydus and Cipla, though below Torrent Pharmaceuticals at 26.76. ROCE of 27.48% is stronger than each of the five peers shown here.
The gap appears most clearly in scale. Gujarat Themis Biosyn’s market cap of Rs 5,897.17 crore is far smaller than all five peers. In other words, the stock combines smaller size with premium valuation and strong return metrics, a mix that can draw attention in both strong and weak market sessions.
Why Investors Are Watching Gujarat Themis Biosyn
- Gujarat Themis Biosyn Share Price fell 5.07% today to Rs 430.15 from Rs 453.10.
- The stock opened at Rs 463.00, hit a low of Rs 427.55 and recorded turnover of Rs 1.57 crore.
- Its P/E of 121.12 and P/B of 5.62 are above industry median and average levels.
- ROE of 21.69% and ROCE of 27.48% remain stronger than industry benchmark medians.
- The company operates in Healthcare and Pharmaceuticals & Drugs, where peer comparison remains relevant after sharp daily moves.
About Gujarat Themis Biosyn
Gujarat Themis Biosyn is part of the Healthcare sector and the Pharmaceuticals & Drugs industry. In this analysis, it is assessed against a same-industry universe of 201 listed companies. Based on the supplied data, it is best viewed as a Mid Cap pharmaceutical stock with above-median scale, premium valuation and stronger-than-average profitability.
Track Gujarat Themis Biosyn Share Price on Univest
UseGujarat Themis Biosyn (GUJTHEM) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Gujarat Themis Biosyn Share Price falling today?
Ans. The stock was down 5.07% in the session, moving from Rs 453.10 to Rs 430.15. The supplied data confirms the decline but does not identify a company-specific reason. The intraday range extended from Rs 427.55 to Rs 463.
What is Gujarat Themis Biosyn Share Price today?
Ans. At the time of the update, the stock was trading at Rs 430.15, which was Rs 22.95 below the previous close of Rs 453.10. The stock moved 5.07% lower during the session.
What does the intraday move show for GUJTHEM?
Ans. GUJTHEM opened at Rs 463.00, which was also the day’s high, then moved down to Rs 427.55 before trading at Rs 430.15. That pattern indicates weakness after the opening level.
How is the stock valued versus its industry?
Ans. Its P/E ratio of 121.12 is above the same-industry median of 32.19 and average of 49.13. Its P/B ratio of 5.62 is also above the benchmark median of 3.05 and average of 4.44.
Are its profitability ratios strong?
Ans. Based on the supplied data, ROE is 21.69% and ROCE is 27.48%. Both are above the same-industry medians and averages listed in the benchmark snapshot. The relevant peer median ROE is 11.82%.
How does it compare with major pharma peers?
Ans. The stock has a higher P/E than Sun Pharma, Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla. Its ROCE of 27.48% is stronger than each of those five peers in the supplied comparison.
